2024
Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce
Willis Z, Oliveira C, Abzug M, Anosike B, Ardura M, Bio L, Boguniewicz J, Chiotos K, Downes K, Grapentine S, Hersh A, Heston S, Hijano D, Huskins W, James S, Jones S, Lockowitz C, Lloyd E, MacBrayne C, Maron G, McDonough M, Miller C, Morton T, Olivero R, Orscheln R, Schwenk H, Singh P, Soma V, Sue P, Vora S, Nakamura M, Wolf J. Guidance for prevention and management of COVID-19 in children and adolescents: A consensus statement from the Pediatric Infectious Diseases Society Pediatric COVID-19 Therapies Taskforce. Journal Of The Pediatric Infectious Diseases Society 2024, 13: 159-185. PMID: 38339996, PMCID: PMC11494238, DOI: 10.1093/jpids/piad116.Peer-Reviewed Original ResearchConceptsRisk factorsRisk stratificationPediatric intensive care medicineEffects of therapyNon-hospitalized childrenPediatric infectious diseasesSevere COVID-19Cases of infectionMeta-analysis of dataIntensive care medicineClinical characteristicsPreventive therapyPediatric populationManagement of COVID-19Fatal infectionConsensus statementSevere illnessTherapyMeta-analysisTherapeutic interventionsSARS-CoV-2Expert consensusCare medicineRe-convenedGuidance statements
2022
Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents
Wolf J, Abzug MJ, Anosike BI, Vora SB, Waghmare A, Sue PK, Olivero RM, Oliveira CR, James SH, Morton TH, Maron GM, Young JL, Orscheln RC, Schwenk HT, Bio LL, Willis ZI, Lloyd EC, Hersh AL, Huskins CW, Soma VL, Ratner AJ, Hayes M, Downes K, Chiotos K, Grapentine SP, Wattier RL, Lamb GS, Zachariah P, Nakamura MM. Updated Guidance on Use and Prioritization of Monoclonal Antibody Therapy for Treatment of COVID-19 in Adolescents. Journal Of The Pediatric Infectious Diseases Society 2022, 11: 177-185. PMID: 35107571, PMCID: PMC8903349, DOI: 10.1093/jpids/piab124.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMonoclonal antibody therapyPediatric infectious diseasesAntibody therapyEmergency use authorizationSevere diseasePostexposure prophylaxisHigh riskCOVID-19Severe acute respiratory syndrome coronavirus 2Certain high-risk conditionsSpecific monoclonal antibody therapyAcute respiratory syndrome coronavirus 2Infectious diseasesRespiratory syndrome coronavirus 2Moderate COVID-19Pediatric critical care medicineSyndrome coronavirus 2Coronavirus disease 2019Critical care medicineHigh-risk conditionsSeries of teleconferencesHigh-risk exposureBamlanivimab monotherapyInfusion reactionsControlled Trials
2021
Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents
Wolf J, Abzug MJ, Wattier RL, Sue PK, Vora SB, Zachariah P, Dulek DE, Waghmare A, Olivero R, Downes KJ, James SH, Pinninti SG, Yarbrough A, Aldrich ML, MacBrayne CE, Soma VL, Grapentine SP, Oliveira CR, Hayes M, Kimberlin DW, Jones SB, Bio LL, Morton TH, Hankins JS, Marόn-Alfaro G, Timberlake K, Young JL, Orscheln RC, Schwenk HT, Goldman DL, Groves HE, Huskins WC, Rajapakse NS, Lamb GS, Tribble AC, Lloyd E, Hersh AL, Thorell EA, Ratner AJ, Chiotos K, Nakamura MM. Initial Guidance on Use of Monoclonal Antibody Therapy for Treatment of Coronavirus Disease 2019 in Children and Adolescents. Journal Of The Pediatric Infectious Diseases Society 2021, 10: 629-634. PMID: 33388760, PMCID: PMC7799019, DOI: 10.1093/jpids/piaa175.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsMonoclonal antibody therapyHigh-risk groupAntibody therapyEmergency use authorizationCOVID-19Moderate coronavirus disease 2019Pediatric intensive care medicinePediatric-specific evidenceTreatment of mildPediatric infectious diseasesHigh-quality evidenceCoronavirus disease 2019Intensive care medicineSeries of teleconferencesREGN-COV2Infusion reactionsPediatric HematologyTimely administrationRisk factorsRoutine administrationDisease 2019Severe diseaseCare medicineHigh riskModest benefit